KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M

KORU Medical Systems, Inc.

2022-Q3 EPS reported -$0.15 revenue$20,551,356

Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.
GAAP net loss $1.2M ($0.03 diluted EPS) vs $1.1M loss ($0.02) in Q3 2021; gross margin 55.7% vs 57.9%.
Full-year 2022 revenue guidance raised to $27.5-28.0M (from $27.0-27.5M); opex guidance lowered to $26.5-27.0M.
Cash $16.4M; management confirms year-end cash minimum of $16.0M.
Novel therapies pipeline: four new Phase II trials, one drug progressed to Phase III.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KORU Medical Systems, Inc. reported full year 2022 results: revenue $27.5 to $28.0 million. Guidance raised.

Period: full year 2022
Revenue: $27.5 to $28.0 million
Guidance: raised
Result: guidance update

Exact text from the filing

KORU Medical now expects full year 2022 revenue to be in the range of $27.5 to $28.0 million (previously $27.0 to $27.5 million).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KORU Medical Systems, Inc. reported the third quarter ended September 30, 2022 results: revenue $7,760,398, net income $1.2 million, EPS $(0.03) per diluted share.

Period: the third quarter ended September 30, 2022
Revenue: $7,760,398
Net income: $1.2 million
EPS: $(0.03) per diluted share
Result: reported results

Exact text from the filing

$ % Net Sales Domestic Core $ 5,900,042 $ 5,076,294 $ 823,748 $ 16.2% International Core 1,096,746 747,281 349,465 46.8% Novel Therapies 763,610 216,969 546,641 251.9% Total $ 7,760,398 $ 6,040,544 $ 1,719,854 $ 28.5% Total net sales increased $1.7 million, or 28.5%, for the three months ended September 30, 2022, as compared with the same period last year as we

View on SEC.gov

Browse all earnings releases →

KORU Medical Systems, Inc. filing history →

Source: SEC EDGAR

accession 0001161697-22-000537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.